Efficacy and Safety of Mirabegron in Intracerebral Hemorrhage

Intracerebral hemorrhage (ICH) accounts for 10-15% of all strokes without effective pharmacological treatment. Inflammation following ICH contributes to barrier disruption and peri-hematoma edema, leading to deterioration of neurological function. Preclinical evidence suggests that bone marrow hematopoietic stem and progenitor cells (HSPCs) are swiftly activated after ICH. Thereafter, these HSPCs produce an increased output of anti-inflammatory monocytes as an endogenous protective mechanism. Stimulation of β3 adrenergic receptor using selective agonists promotes the production of anti-inflammatory monocytes in bone marrow, and thereby reduces neuroinflammation, brain edema and neurological deficits. This study is to assess the safety and efficacy of a β3 adrenergic receptor agonist Mirabegron as a potential treatment option in ICH patients.

NCT Number	NCT05369351
Lead Sponsor	Tianjin Medical University General Hospital
Conditions	Intracerebral Haemorrhage
Enrollment	25 participants
Start Date	2024-01-17
Primary Completion	2026-08-10 (estimated)
Study Completion	2026-11-10 (estimated)
Updated on ClinicalTrials.gov	2025-05-28